Patents for A61P 17 - Drugs for dermatological disorders (106,455)
02/2005
02/17/2005WO2004093781A3 Podophyllotoxin derivatives as igf-1r inhibitors
02/17/2005WO2004091558A3 Compounds for stimulating and for inhibiting melanin formation, and methods for screening these compounds
02/17/2005WO2004070050A3 Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors
02/17/2005WO2003099192A8 Bis-aromatic alkanols
02/17/2005WO2003080568A3 Probucol derivatives
02/17/2005WO2003070910A3 INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
02/17/2005WO2003025131A3 Protein modification and maintenance molecules
02/17/2005WO2002074913A3 Nucleic acid-associated proteins
02/17/2005US20050038505 Drug-delivery endovascular stent and method of forming the same
02/17/2005US20050038259 Elastase release inhibitors; such as 19-(1H-tetrazol-5-yl)nonadec-6-en-5-ol
02/17/2005US20050038243 2, 4-pyrimidinediamine compounds and their uses
02/17/2005US20050038119 for treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis; prevention and treatment of damages caused by ischemia and reperfusion
02/17/2005US20050038095 Azolylbenzamides and analogues and their use for treating osteoporosis
02/17/2005US20050038084 Phenylalanine enamide derivatives
02/17/2005US20050038072 Nitrogeneous cyclic ketone derivative, process for producing the same, and use
02/17/2005US20050038069 Tumor necrosis factor antagonist; antiinflammatory agents; such as 2-Cyclopropyl-4-(3,5-dimethyl-4-pyridylmethoxy)-7-methoxy-3H-benzimidazole
02/17/2005US20050038034 Analgesics; neurodegenerative disorders; multiple sclerosis; Parkinson's disease; neuropathic pain
02/17/2005US20050038023 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease
02/17/2005US20050038014 5'-carbamoyl-1,1' biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
02/17/2005US20050038010 Substituted heterocyclic compounds and methods of use
02/17/2005US20050038009 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- alpha -[N-((S)-1-carboxypropyl) carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine
02/17/2005US20050037494 Using antisense agents to reduce and/or prevention genic expression associated with cardi-vascular complications; gene therapy
02/17/2005US20050037096 Dispersed solid-containing complex carbohydrate
02/17/2005US20050037093 Treatment of nail infections with no
02/17/2005US20050037087 Microcapsular composition comprising core, including at least one active ingredient in combination with an oil or mixture of oils, wherein oils alone or in combination with active ingredient have specific gravity higher than that of water; microcapsules can be easily isolated by precipitation
02/17/2005US20050037069 Solid and stable creatine/citric acid composition(s) and compositions carbohydrate(s) or hydrates thereof, method for the production and use thereof
02/17/2005US20050037060 topical mixture of minoxidil or salts, solubilizers, solvents and cosolvents, used for the treatment of alopecia
02/17/2005US20050037028 Topical antiallergenic cream containing Asian longhorn beetle wastes; animal extracts
02/17/2005US20050037024 Matrix metalloprotease inhibitor
02/17/2005US20050037009 Methods and reagents for protease inhibition
02/17/2005US20050037005 5c8 Antigen
02/17/2005US20050037003 Administering a soluble lymphotoxin- beta receptor, an antibody directed against LT- beta receptor, or an antibody directed against surface LT ligand with a carrier; multiple sclerosis, vision defects, psoriasis, inflammatory bowel disease; antidiabetic agents
02/17/2005US20050036985 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
02/17/2005US20050036966 Medicine for preventing and treating bromidrosis
02/17/2005US20050036960 contains a suspending agent (a clay like montmorillonite), a rinse-off resistant agent (maleic anyhydride terpolymers, polyvinylpyrillidone, and copolymers) and a skin protectant agent (oatmeal, soy, zinc oxide); free of oil and silicone
02/17/2005US20050035267 Furnace mount and method of installation
02/17/2005US20050035266 Furnace Mount and Method of Installation
02/17/2005DE10332011A1 Verwendung von Glaszusammensetzungen zum Erzielen eines antioxidativen Effektes Use of glass compositions to achieve an anti-oxidative effect
02/17/2005CA2536486A1 Steroid derivatives and use thereof as medicaments
02/17/2005CA2535125A1 Pyridylpyrrole derivatives active as kinase inhibitors
02/17/2005CA2535066A1 Macrophage activation inhibitor
02/17/2005CA2534905A1 Pyridyl piperazinyl ureas
02/17/2005CA2534645A1 Composition and method for promoting hair growth
02/17/2005CA2534496A1 Pyrimidylpyrrole derivatives active as kinase inhibitors
02/17/2005CA2534102A1 Use of spermine and/or spermidine against skin ageing in dietary, pharmaceutical or cosmetic compositions
02/17/2005CA2533329A1 New therapeutic use of chondroitin sulphate
02/16/2005EP1506999A1 Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
02/16/2005EP1506967A1 Dipeptidyl peptidase inhibitors
02/16/2005EP1506962A2 Nitrogen-containing aromatic heterocycles
02/16/2005EP1506958A1 Process for producing shogaol and intermediates for the synthesis thereof
02/16/2005EP1506782A1 Vapor fraction from seeds of glycine max (L.) merr. and composition thereof
02/16/2005EP1506775A1 Use of sex steroid function modulators to treat wounds and fibrotic disorders
02/16/2005EP1506773A1 Sprayable skin protectant compositions
02/16/2005EP1506409A1 Assays for modulators of asparaginyl hydroxylase
02/16/2005EP1506286A2 Neutralizing human anti-igfr antibody
02/16/2005EP1506285A2 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
02/16/2005EP1506214A1 6-11 bicyclic ketolide derivatives
02/16/2005EP1506211A1 C-aryl glucoside sglt2 inhibitors and method
02/16/2005EP1506205A2 Novel azacyclic ethynyl derivatives
02/16/2005EP1506204A2 1-oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
02/16/2005EP1506202A1 1-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the prepartion thereof
02/16/2005EP1506200A2 Novel diazabicyclic biaryl derivatives
02/16/2005EP1506192A1 Substituted pyrroline kinase inhibitors
02/16/2005EP1506191A1 Benzoxazine and benzoxazinone substituted triazoles
02/16/2005EP1506187A1 2-thio-substituted imidazole derivatives and their use in pharmaceutics
02/16/2005EP1506186A1 Substituted heterocyclic compounds and methods of use
02/16/2005EP1506176A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
02/16/2005EP1506011A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
02/16/2005EP1506002A2 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
02/16/2005EP1505988A1 Dual dispenser for aesthetically acceptable delivery of anhydrous skin treatment compositions
02/16/2005EP1505984A2 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
02/16/2005EP1505979A1 Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles
02/16/2005EP1505973A2 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
02/16/2005EP1505953A2 Novel polyol-glycoside compositions for the skin
02/16/2005EP1505930A2 Drug-delivery endovascular stent and method for treating restenosis
02/16/2005EP1425258A4 Hydroxyeicosenoic acid analogs
02/16/2005EP1421099B1 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents
02/16/2005EP1397365B1 Heteroaryl-diazabicyclo-alkanes as cns-modulators
02/16/2005EP1339417B1 Preparation for the treatment of surface open wounds
02/16/2005EP1296698A4 Therapeutic agents - ii
02/16/2005EP1296697A4 Therapeutic agents - i
02/16/2005EP1246814B1 Compounds and methods for modulation of estrogen receptors
02/16/2005EP1240166B1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl carboxamide inhibitors of cyclin dependent kinases
02/16/2005EP1215203B1 Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient
02/16/2005EP1181329B1 Silicone gel containing salicylic acid
02/16/2005EP0634896B1 Evaluation of patients with progressive immunosuppression
02/16/2005CN1582302A Dermopharmaceutically and cosmetically active oligopeptides
02/16/2005CN1582301A Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
02/16/2005CN1582287A Thiophenylthiopyrane dioxides as MMP or TNF-alpha inhibitors
02/16/2005CN1582286A Novel 4-2-furoylaminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same
02/16/2005CN1582285A Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (GSK3 inhibitors)
02/16/2005CN1582284A Aminopyrimidines and pyridines
02/16/2005CN1582283A Benzothiepine ileal bile acid transport inhibitors
02/16/2005CN1582280A 3, 4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
02/16/2005CN1582277A Amide derivatives as glycogen synthase kinase 3-beta inhibitors
02/16/2005CN1582276A Phenylalanine enamide derivatives
02/16/2005CN1582271A Inhibitors of integrin alpha v beta 6
02/16/2005CN1582269A Hydroxyeicosenoic acid analogs
02/16/2005CN1582161A Pharmatceutical Formualtion comprising cyclosporin and use thereof
02/16/2005CN1582158A Novel therapeutic indication of azithromycin for treatment of non-infective inflammatory diseases